NO323610B1 - Polypeptider og peptider som omfatter en hemoglobin-alfa-kjede eller deler derav, farmasoytiske blandinger som omfatter dem, samt anvendelser og fremgangsmater som involverer stamcelleproliferasjonsinhiberende og -stimulerende mengder av polypeptidene og peptidene. - Google Patents

Info

Publication number

NO323610B1

NO323610B1 NO19984628A NO984628A NO323610B1 NO 323610 B1 NO323610 B1 NO 323610B1 NO 19984628 A NO19984628 A NO 19984628A NO 984628 A NO984628 A NO 984628A NO 323610 B1 NO323610 B1 NO 323610B1

Authority

NO

Norway

Prior art keywords

hemoglobin

cells

chain

polypeptide

stem cell

Prior art date

1996-04-03

Links

• Espacenet
• Global Dossier
• Discuss

• 210000000130 stem cell Anatomy 0.000 title claims abstract description 277
• 238000000034 method Methods 0.000 title claims abstract description 75
• 230000004663 cell proliferation Effects 0.000 title claims abstract description 29
• 108090000765 processed proteins & peptides Proteins 0.000 title claims description 181
• 102000004196 processed proteins & peptides Human genes 0.000 title claims description 141
• 229920001184 polypeptide Polymers 0.000 title claims description 90
• 230000002401 inhibitory effect Effects 0.000 title claims description 59
• 230000004936 stimulating effect Effects 0.000 title claims description 44
• 108091005902 Hemoglobin subunit alpha Proteins 0.000 title claims description 16
• 102100027685 Hemoglobin subunit alpha Human genes 0.000 title claims description 16
• 239000008194 pharmaceutical composition Substances 0.000 title description 4
• 238000002512 chemotherapy Methods 0.000 claims abstract description 30
• 210000004976 peripheral blood cell Anatomy 0.000 claims abstract description 7
• 210000004027 cell Anatomy 0.000 claims description 156
• 241000282414 Homo sapiens Species 0.000 claims description 102
• 108010054147 Hemoglobins Proteins 0.000 claims description 80
• 102000001554 Hemoglobins Human genes 0.000 claims description 80
• 238000012360 testing method Methods 0.000 claims description 72
• 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 71
• 239000000203 mixture Substances 0.000 claims description 64
• 238000011282 treatment Methods 0.000 claims description 59
• 150000001413 amino acids Chemical class 0.000 claims description 57
• 102000005962 receptors Human genes 0.000 claims description 31
• 108020003175 receptors Proteins 0.000 claims description 31
• 239000003814 drug Substances 0.000 claims description 30
• 238000002360 preparation method Methods 0.000 claims description 30
• 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 claims description 28
• 150000001875 compounds Chemical class 0.000 claims description 26
• 229940079593 drug Drugs 0.000 claims description 21
• 230000014509 gene expression Effects 0.000 claims description 21
• 102000004127 Cytokines Human genes 0.000 claims description 20
• 108090000695 Cytokines Proteins 0.000 claims description 20
• 108010002386 Interleukin-3 Proteins 0.000 claims description 19
• 102000000646 Interleukin-3 Human genes 0.000 claims description 19
• 206010028980 Neoplasm Diseases 0.000 claims description 19
• -1 IL-14 Proteins 0.000 claims description 18
• 210000004899 c-terminal region Anatomy 0.000 claims description 18
• 238000004519 manufacturing process Methods 0.000 claims description 18
• 108090000848 Ubiquitin Proteins 0.000 claims description 17
• 210000002798 bone marrow cell Anatomy 0.000 claims description 17
• 230000002209 hydrophobic effect Effects 0.000 claims description 17
• 230000005855 radiation Effects 0.000 claims description 17
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 15
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 15
• 102000044159 Ubiquitin Human genes 0.000 claims description 15
• 201000011510 cancer Diseases 0.000 claims description 15
• 239000000463 material Substances 0.000 claims description 14
• 102000014702 Haptoglobin Human genes 0.000 claims description 13
• 108050005077 Haptoglobin Proteins 0.000 claims description 13
• 241000124008 Mammalia Species 0.000 claims description 13
• 230000004224 protection Effects 0.000 claims description 13
• 210000004700 fetal blood Anatomy 0.000 claims description 12
• 230000010261 cell growth Effects 0.000 claims description 11
• 230000004927 fusion Effects 0.000 claims description 11
• 230000003394 haemopoietic effect Effects 0.000 claims description 11
• 102000003951 Erythropoietin Human genes 0.000 claims description 10
• 108090000394 Erythropoietin Proteins 0.000 claims description 10
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 10
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 10
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 10
• 238000012217 deletion Methods 0.000 claims description 10
• 230000037430 deletion Effects 0.000 claims description 10
• 229940105423 erythropoietin Drugs 0.000 claims description 10
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 10
• 108010002586 Interleukin-7 Proteins 0.000 claims description 9
• 230000002062 proliferating effect Effects 0.000 claims description 9
• 108700014844 flt3 ligand Proteins 0.000 claims description 8
• 238000001415 gene therapy Methods 0.000 claims description 8
• 208000030507 AIDS Diseases 0.000 claims description 7
• 241000588724 Escherichia coli Species 0.000 claims description 7
• 238000006467 substitution reaction Methods 0.000 claims description 7
• 108090000978 Interleukin-4 Proteins 0.000 claims description 6
• 108010002616 Interleukin-5 Proteins 0.000 claims description 6
• 108090001005 Interleukin-6 Proteins 0.000 claims description 6
• 210000004185 liver Anatomy 0.000 claims description 6
• 230000002265 prevention Effects 0.000 claims description 6
• 108010002352 Interleukin-1 Proteins 0.000 claims description 5
• 108090000177 Interleukin-11 Proteins 0.000 claims description 5
• 108090000176 Interleukin-13 Proteins 0.000 claims description 5
• 108010002350 Interleukin-2 Proteins 0.000 claims description 5
• 108010002335 Interleukin-9 Proteins 0.000 claims description 5
• 102000036693 Thrombopoietin Human genes 0.000 claims description 5
• 108010041111 Thrombopoietin Proteins 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 102000004190 Enzymes Human genes 0.000 claims description 4
• 108090000790 Enzymes Proteins 0.000 claims description 4
• 102000003812 Interleukin-15 Human genes 0.000 claims description 4
• 108090000172 Interleukin-15 Proteins 0.000 claims description 4
• 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims description 4
• 208000014767 Myeloproliferative disease Diseases 0.000 claims description 4
• 102000030621 adenylate cyclase Human genes 0.000 claims description 4
• 108060000200 adenylate cyclase Proteins 0.000 claims description 4
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
• 230000003308 immunostimulating effect Effects 0.000 claims description 4
• 125000002346 iodo group Chemical group I* 0.000 claims description 4
• 208000023275 Autoimmune disease Diseases 0.000 claims description 3
• 206010061598 Immunodeficiency Diseases 0.000 claims description 3
• 208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
• 230000007813 immunodeficiency Effects 0.000 claims description 3
• 230000001939 inductive effect Effects 0.000 claims description 3
• 230000001681 protective effect Effects 0.000 claims description 3
• WMMKLGOAKIPZJN-YTFOTSKYSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-3-carboxy-2-[[(2s)-4-carboxy-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]butanoyl]amino]propanoyl]amino]-3-sulfanylpropanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCC(=O)N1 WMMKLGOAKIPZJN-YTFOTSKYSA-N 0.000 claims description 2
• HJDRXEQUFWLOGJ-AJNGGQMLSA-N Ac-Ser-Asp-Lys-Pro-OH Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(O)=O HJDRXEQUFWLOGJ-AJNGGQMLSA-N 0.000 claims description 2
• 108010024636 Glutathione Proteins 0.000 claims description 2
• 108700012920 TNF Proteins 0.000 claims description 2
• 230000036592 analgesia Effects 0.000 claims description 2
• 208000007502 anemia Diseases 0.000 claims description 2
• 229960003180 glutathione Drugs 0.000 claims description 2
• 108010031357 goralatide Proteins 0.000 claims description 2
• 230000002071 myeloproliferative effect Effects 0.000 claims description 2
• 230000036407 pain Effects 0.000 claims description 2
• 210000003954 umbilical cord Anatomy 0.000 claims description 2
• VDMABHYXBULDGN-LAEOZQHASA-N Gln-Val-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O VDMABHYXBULDGN-LAEOZQHASA-N 0.000 claims 1
• 210000004524 haematopoietic cell Anatomy 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 abstract description 36
• 230000022131 cell cycle Effects 0.000 abstract description 22
• 238000011084 recovery Methods 0.000 abstract description 11
• 238000002955 isolation Methods 0.000 abstract description 2
• 230000001105 regulatory effect Effects 0.000 abstract description 2
• 230000000694 effects Effects 0.000 description 72
• 210000001185 bone marrow Anatomy 0.000 description 71
• 108090000623 proteins and genes Proteins 0.000 description 61
• 241000699670 Mus sp. Species 0.000 description 57
• 235000001014 amino acid Nutrition 0.000 description 41
• 229940024606 amino acid Drugs 0.000 description 39
• 102000004169 proteins and genes Human genes 0.000 description 34
• 238000001727 in vivo Methods 0.000 description 31
• 235000018102 proteins Nutrition 0.000 description 31
• 239000002609 medium Substances 0.000 description 30
• 230000035755 proliferation Effects 0.000 description 29
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 26
• 229940127240 opiate Drugs 0.000 description 24
• 238000000746 purification Methods 0.000 description 24
• PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 23
• 229960001712 testosterone propionate Drugs 0.000 description 23
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 22
• 241000699666 Mus <mouse, genus> Species 0.000 description 22
• 229960002949 fluorouracil Drugs 0.000 description 22
• 239000000499 gel Substances 0.000 description 21
• 208000032839 leukemia Diseases 0.000 description 21
• 102000000013 Chemokine CCL3 Human genes 0.000 description 20
• 230000001351 cycling effect Effects 0.000 description 20
• 101710155856 C-C motif chemokine 3 Proteins 0.000 description 18
• 229940127089 cytotoxic agent Drugs 0.000 description 18
• 229940076264 interleukin-3 Drugs 0.000 description 18
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 18
• 239000000047 product Substances 0.000 description 18
• 241001465754 Metazoa Species 0.000 description 17
• 238000011534 incubation Methods 0.000 description 17
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 16
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
• 238000000338 in vitro Methods 0.000 description 16
• 230000007774 longterm Effects 0.000 description 16
• 210000003643 myeloid progenitor cell Anatomy 0.000 description 16
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 14
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 14
• 241001529936 Murinae Species 0.000 description 14
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 14
• 239000002246 antineoplastic agent Substances 0.000 description 14
• 210000004369 blood Anatomy 0.000 description 14
• 239000008280 blood Substances 0.000 description 14
• 239000012634 fragment Substances 0.000 description 14
• 230000005764 inhibitory process Effects 0.000 description 14
• 238000002347 injection Methods 0.000 description 14
• 239000007924 injection Substances 0.000 description 14
• 238000001959 radiotherapy Methods 0.000 description 14
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 14
• 229960004127 naloxone Drugs 0.000 description 13
• UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 13
• 238000011533 pre-incubation Methods 0.000 description 13
• 102000001490 Opioid Peptides Human genes 0.000 description 12
• 108010093625 Opioid Peptides Proteins 0.000 description 12
• 238000010322 bone marrow transplantation Methods 0.000 description 12
• 230000001965 increasing effect Effects 0.000 description 12
• 239000003399 opiate peptide Substances 0.000 description 12
• 230000004083 survival effect Effects 0.000 description 12
• 229940104230 thymidine Drugs 0.000 description 12
• 230000004069 differentiation Effects 0.000 description 11
• 150000003278 haem Chemical class 0.000 description 11
• 230000011132 hemopoiesis Effects 0.000 description 11
• 210000005259 peripheral blood Anatomy 0.000 description 11
• 239000011886 peripheral blood Substances 0.000 description 11
• 239000013612 plasmid Substances 0.000 description 11
• UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 10
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
• 102400001111 Nociceptin Human genes 0.000 description 10
• 108090000622 Nociceptin Proteins 0.000 description 10
• 108090000137 Opioid Receptors Proteins 0.000 description 10
• 102000003840 Opioid Receptors Human genes 0.000 description 10
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
• 230000001464 adherent effect Effects 0.000 description 10
• 210000000601 blood cell Anatomy 0.000 description 10
• 239000000872 buffer Substances 0.000 description 10
• 239000003795 chemical substances by application Substances 0.000 description 10
• 239000002299 complementary DNA Substances 0.000 description 10
• PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 description 10
• 238000004007 reversed phase HPLC Methods 0.000 description 10
• UEVAHGMTRWGMTB-JBXUNAHCSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 UEVAHGMTRWGMTB-JBXUNAHCSA-N 0.000 description 9
• 125000003275 alpha amino acid group Chemical group 0.000 description 9
• 239000005557 antagonist Substances 0.000 description 9
• 238000003556 assay Methods 0.000 description 9
• 208000035475 disorder Diseases 0.000 description 9
• 239000003102 growth factor Substances 0.000 description 9
• 229960005181 morphine Drugs 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• 238000002054 transplantation Methods 0.000 description 9
• 108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 8
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 8
• 102100021519 Hemoglobin subunit beta Human genes 0.000 description 8
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 8
• 108010062374 Myoglobin Proteins 0.000 description 8
• 102100030856 Myoglobin Human genes 0.000 description 8
• SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 8
• 230000018199 S phase Effects 0.000 description 8
• 239000000284 extract Substances 0.000 description 8
• 108020001507 fusion proteins Proteins 0.000 description 8
• 102000037865 fusion proteins Human genes 0.000 description 8
• 229960003604 testosterone Drugs 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 238000002560 therapeutic procedure Methods 0.000 description 8
• 108010094098 tyrosyl-arginyl-phenylalanyl-lysinamide Proteins 0.000 description 8
• PZWWYAHWHHNCHO-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-(3-aminopropyl)-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 PZWWYAHWHHNCHO-FGHAYEPSSA-N 0.000 description 7
• HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 7
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 7
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 7
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
• 239000000556 agonist Substances 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 201000010099 disease Diseases 0.000 description 7
• 238000005516 engineering process Methods 0.000 description 7
• 229920000609 methyl cellulose Polymers 0.000 description 7
• 239000001923 methylcellulose Substances 0.000 description 7
• 235000010981 methylcellulose Nutrition 0.000 description 7
• 210000005087 mononuclear cell Anatomy 0.000 description 7
• 108700040302 phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide Proteins 0.000 description 7
• 230000007017 scission Effects 0.000 description 7
• 210000000952 spleen Anatomy 0.000 description 7
• 238000010561 standard procedure Methods 0.000 description 7
• 210000000689 upper leg Anatomy 0.000 description 7
• 239000013598 vector Substances 0.000 description 7
• IDLAOWFFKWRNHB-UHFFFAOYSA-N 4,5,6,7-tetrachloroindene-1,3-dione Chemical compound ClC1=C(Cl)C(Cl)=C2C(=O)CC(=O)C2=C1Cl IDLAOWFFKWRNHB-UHFFFAOYSA-N 0.000 description 6
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 6
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
• 239000007983 Tris buffer Substances 0.000 description 6
• 102100025040 Ubiquitin carboxyl-terminal hydrolase isozyme L3 Human genes 0.000 description 6
• 101710186831 Ubiquitin carboxyl-terminal hydrolase isozyme L3 Proteins 0.000 description 6
• 230000009471 action Effects 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 230000004071 biological effect Effects 0.000 description 6
• 230000037396 body weight Effects 0.000 description 6
• 238000005119 centrifugation Methods 0.000 description 6
• 230000003021 clonogenic effect Effects 0.000 description 6
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 6
• 231100000433 cytotoxic Toxicity 0.000 description 6
• 230000001472 cytotoxic effect Effects 0.000 description 6
• 230000006378 damage Effects 0.000 description 6
• 210000003013 erythroid precursor cell Anatomy 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 239000012071 phase Substances 0.000 description 6
• 239000002244 precipitate Substances 0.000 description 6
• 210000002966 serum Anatomy 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 239000006228 supernatant Substances 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• 238000012546 transfer Methods 0.000 description 6
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 229920001817 Agar Polymers 0.000 description 5
• 108091028043 Nucleic acid sequence Proteins 0.000 description 5
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
• 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 5
• 239000008272 agar Substances 0.000 description 5
• 230000001580 bacterial effect Effects 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 239000003636 conditioned culture medium Substances 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 238000010828 elution Methods 0.000 description 5
• 210000003743 erythrocyte Anatomy 0.000 description 5
• 108010020477 exorphins Proteins 0.000 description 5
• 230000001605 fetal effect Effects 0.000 description 5
• 229940025294 hemin Drugs 0.000 description 5
• BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 5
• 238000004128 high performance liquid chromatography Methods 0.000 description 5
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 5
• 238000010348 incorporation Methods 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 230000008929 regeneration Effects 0.000 description 5
• 238000011069 regeneration method Methods 0.000 description 5
• 238000012216 screening Methods 0.000 description 5
• 238000000926 separation method Methods 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 108700043026 tyrosyl-prolyl-leucyl-glycinamide Proteins 0.000 description 5
• IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 4
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
• 108020004414 DNA Proteins 0.000 description 4
• 108010092674 Enkephalins Proteins 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 4
• 229930193140 Neomycin Natural products 0.000 description 4
• 108091034117 Oligonucleotide Proteins 0.000 description 4
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
• UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 4
• 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 4
• 239000007997 Tricine buffer Substances 0.000 description 4
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
• 230000032683 aging Effects 0.000 description 4
• 125000000539 amino acid group Chemical group 0.000 description 4
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 4
• 235000011130 ammonium sulphate Nutrition 0.000 description 4
• 230000001332 colony forming effect Effects 0.000 description 4
• 229960004397 cyclophosphamide Drugs 0.000 description 4
• 239000002254 cytotoxic agent Substances 0.000 description 4
• KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 238000001962 electrophoresis Methods 0.000 description 4
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
• 230000000925 erythroid effect Effects 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 210000000777 hematopoietic system Anatomy 0.000 description 4
• 230000003463 hyperproliferative effect Effects 0.000 description 4
• 230000001976 improved effect Effects 0.000 description 4
• 238000001802 infusion Methods 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• 239000010410 layer Substances 0.000 description 4
• 239000006166 lysate Substances 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
• 229960004927 neomycin Drugs 0.000 description 4
• 239000008188 pellet Substances 0.000 description 4
• 230000002093 peripheral effect Effects 0.000 description 4
• 238000007747 plating Methods 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 230000017854 proteolysis Effects 0.000 description 4
• 230000002285 radioactive effect Effects 0.000 description 4
• 230000002629 repopulating effect Effects 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• YFGBQHOOROIVKG-BHDDXSALSA-N (2R)-2-[[(2R)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@H](C(=O)N[C@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-BHDDXSALSA-N 0.000 description 3
• ZHUJMSMQIPIPTF-IBURTVSXSA-N (2r)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ZHUJMSMQIPIPTF-IBURTVSXSA-N 0.000 description 3
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
• 108010088751 Albumins Proteins 0.000 description 3
• 102000009027 Albumins Human genes 0.000 description 3
• 206010002961 Aplasia Diseases 0.000 description 3
• 208000032467 Aplastic anaemia Diseases 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
• 102000011632 Caseins Human genes 0.000 description 3
• 108010076119 Caseins Proteins 0.000 description 3
• 206010010144 Completed suicide Diseases 0.000 description 3
• 108010065372 Dynorphins Proteins 0.000 description 3
• 108010049140 Endorphins Proteins 0.000 description 3
• 102000009025 Endorphins Human genes 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 229920001917 Ficoll Polymers 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101001122499 Homo sapiens Nociceptin receptor Proteins 0.000 description 3
• 101000747867 Homo sapiens Upstream-binding protein 1 Proteins 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
• 108010004028 Leucine-2-Alanine Enkephalin Proteins 0.000 description 3
• 102400000988 Met-enkephalin Human genes 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 108010042237 Methionine Enkephalin Proteins 0.000 description 3
• 102100028646 Nociceptin receptor Human genes 0.000 description 3
• 102100024622 Proenkephalin-B Human genes 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 241000282887 Suidae Species 0.000 description 3
• 102100040065 Upstream-binding protein 1 Human genes 0.000 description 3
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
• 229930013930 alkaloid Natural products 0.000 description 3
• 229960000723 ampicillin Drugs 0.000 description 3
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 239000006285 cell suspension Substances 0.000 description 3
• 230000000973 chemotherapeutic effect Effects 0.000 description 3
• 238000010367 cloning Methods 0.000 description 3
• 229960004126 codeine Drugs 0.000 description 3
• 231100000599 cytotoxic agent Toxicity 0.000 description 3
• 238000011393 cytotoxic chemotherapy Methods 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 230000029087 digestion Effects 0.000 description 3
• XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 3
• JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 229950004155 etorphine Drugs 0.000 description 3
• CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 3
• 239000012467 final product Substances 0.000 description 3
• 210000003714 granulocyte Anatomy 0.000 description 3
• 238000003306 harvesting Methods 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 238000010253 intravenous injection Methods 0.000 description 3
• 238000011835 investigation Methods 0.000 description 3
• 231100000518 lethal Toxicity 0.000 description 3
• 230000001665 lethal effect Effects 0.000 description 3
• 210000002540 macrophage Anatomy 0.000 description 3
• 238000012261 overproduction Methods 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 235000008729 phenylalanine Nutrition 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000001177 retroviral effect Effects 0.000 description 3
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 239000000243 solution Substances 0.000 description 3
• 230000024642 stem cell division Effects 0.000 description 3
• 210000002536 stromal cell Anatomy 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 238000000539 two dimensional gel electrophoresis Methods 0.000 description 3
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• GYNQVPIDAQTZOY-ROUUACIJSA-N (2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](N)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 GYNQVPIDAQTZOY-ROUUACIJSA-N 0.000 description 2
• ABTNETSDXZBJTE-WLHGVMLRSA-N (e)-but-2-enedioic acid;methyl 4-[2-(3,4-dichlorophenyl)acetyl]-3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate Chemical compound OC(=O)\C=C\C(O)=O.C1N(C(=O)OC)CCN(C(=O)CC=2C=C(Cl)C(Cl)=CC=2)C1CN1CCCC1 ABTNETSDXZBJTE-WLHGVMLRSA-N 0.000 description 2
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
• 101800000504 3C-like protease Proteins 0.000 description 2
• 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
• 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 102000004506 Blood Proteins Human genes 0.000 description 2
• 108010017384 Blood Proteins Proteins 0.000 description 2
• 108700012434 CCL3 Proteins 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
• 108700010070 Codon Usage Proteins 0.000 description 2
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
• 229920000742 Cotton Polymers 0.000 description 2
• 108700022182 D-Penicillamine (2,5)- Enkephalin Proteins 0.000 description 2
• MCMMCRYPQBNCPH-WMIMKTLMSA-N DPDPE Chemical compound C([C@H](N)C(=O)N[C@@H]1C(C)(C)SSC([C@@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)CNC1=O)C(O)=O)(C)C)C1=CC=C(O)C=C1 MCMMCRYPQBNCPH-WMIMKTLMSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
• 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 2
• 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 2
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 102000015696 Interleukins Human genes 0.000 description 2
• 108010063738 Interleukins Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 108010022337 Leucine Enkephalin Proteins 0.000 description 2
• JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 2
• XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
• 239000000020 Nitrocellulose Substances 0.000 description 2
• BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
• UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 2
• 238000012408 PCR amplification Methods 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 239000004743 Polypropylene Substances 0.000 description 2
• 108091008109 Pseudogenes Proteins 0.000 description 2
• 102000057361 Pseudogenes Human genes 0.000 description 2
• 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• 108010056088 Somatostatin Proteins 0.000 description 2
• 102000005157 Somatostatin Human genes 0.000 description 2
• 102000015215 Stem Cell Factor Human genes 0.000 description 2
• 108010039445 Stem Cell Factor Proteins 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 239000003443 antiviral agent Substances 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 238000004166 bioassay Methods 0.000 description 2
• RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
• 229960001736 buprenorphine Drugs 0.000 description 2
• 230000032823 cell division Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 238000001311 chemical methods and process Methods 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 229940047120 colony stimulating factors Drugs 0.000 description 2
• 230000003750 conditioning effect Effects 0.000 description 2
• 238000012937 correction Methods 0.000 description 2
• 238000009109 curative therapy Methods 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 108700023159 delta Opioid Receptors Proteins 0.000 description 2
• 102000048124 delta Opioid Receptors Human genes 0.000 description 2
• 230000001066 destructive effect Effects 0.000 description 2
• 229960002069 diamorphine Drugs 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 229960004192 diphenoxylate Drugs 0.000 description 2
• HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 229960002428 fentanyl Drugs 0.000 description 2
• PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 235000019253 formic acid Nutrition 0.000 description 2
• 238000007710 freezing Methods 0.000 description 2
• 230000008014 freezing Effects 0.000 description 2
• 238000001502 gel electrophoresis Methods 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 2
• 210000002443 helper t lymphocyte Anatomy 0.000 description 2
• 230000002489 hematologic effect Effects 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 102000055647 human CSF2RB Human genes 0.000 description 2
• 238000009396 hybridization Methods 0.000 description 2
• LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
• 229960000240 hydrocodone Drugs 0.000 description 2
• WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 2
• 229960001410 hydromorphone Drugs 0.000 description 2
• 229960001330 hydroxycarbamide Drugs 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 229940047122 interleukins Drugs 0.000 description 2
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
• 102000048260 kappa Opioid Receptors Human genes 0.000 description 2
• URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 2
• 229960003406 levorphanol Drugs 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 239000012160 loading buffer Substances 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
• 230000000813 microbial effect Effects 0.000 description 2
• 230000001400 myeloablative effect Effects 0.000 description 2
• 210000001087 myotubule Anatomy 0.000 description 2
• AJPSBXJNFJCCBI-YOHUGVJRSA-N naloxonazine Chemical compound C([C@@H](N(CC1)CC=C)[C@]2(O)CC\C3=N/N=C4/[C@H]5[C@]67CCN(CC=C)[C@@H]([C@@]7(CC4)O)CC4=CC=C(C(O5)=C46)O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 AJPSBXJNFJCCBI-YOHUGVJRSA-N 0.000 description 2
• DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
• 229960003086 naltrexone Drugs 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 229920001220 nitrocellulos Polymers 0.000 description 2
• 210000003924 normoblast Anatomy 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 239000003401 opiate antagonist Substances 0.000 description 2
• 238000005457 optimization Methods 0.000 description 2
• 229960002085 oxycodone Drugs 0.000 description 2
• 229960005118 oxymorphone Drugs 0.000 description 2
• 101800000607 p15 Proteins 0.000 description 2
• 229960000482 pethidine Drugs 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 2
• 229940067157 phenylhydrazine Drugs 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920001155 polypropylene Polymers 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• 239000012460 protein solution Substances 0.000 description 2
• 239000013014 purified material Substances 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 239000002994 raw material Substances 0.000 description 2
• 239000011535 reaction buffer Substances 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 230000001172 regenerating effect Effects 0.000 description 2
• 230000000284 resting effect Effects 0.000 description 2
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 239000002356 single layer Substances 0.000 description 2
• 239000007974 sodium acetate buffer Substances 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 238000010532 solid phase synthesis reaction Methods 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
• 229960000553 somatostatin Drugs 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 238000011476 stem cell transplantation Methods 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 238000010257 thawing Methods 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
• 230000007704 transition Effects 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 108010012567 tyrosyl-glycyl-glycyl-phenylalanyl Proteins 0.000 description 2
• 238000000108 ultra-filtration Methods 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• 108020001588 κ-opioid receptors Proteins 0.000 description 2
• UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• XJOQRTJDYAHKPY-MWSMAVIUSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-n-[(2s)-1-[[(2s)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-o Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 XJOQRTJDYAHKPY-MWSMAVIUSA-N 0.000 description 1
• PAJVBIPSWDYNHN-JMJBHNTOSA-N (2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s,3r)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]a Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 PAJVBIPSWDYNHN-JMJBHNTOSA-N 0.000 description 1
• MVUYXNQARFGHMJ-DCSNJQJVSA-N (2s)-2-amino-n-[(2r)-1-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 MVUYXNQARFGHMJ-DCSNJQJVSA-N 0.000 description 1
• AGTSSZRZBSNTGQ-ITZCFHCWSA-N (2s,3r)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomet Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 AGTSSZRZBSNTGQ-ITZCFHCWSA-N 0.000 description 1
• INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
• NWFLONJLUJYCNS-UHFFFAOYSA-N 2-[[2-[[2-[(2-amino-3-phenylpropanoyl)amino]acetyl]amino]acetyl]amino]-3-phenylpropanoic acid Chemical compound C=1C=CC=CC=1CC(C(O)=O)NC(=O)CNC(=O)CNC(=O)C(N)CC1=CC=CC=C1 NWFLONJLUJYCNS-UHFFFAOYSA-N 0.000 description 1
• USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 102000004400 Aminopeptidases Human genes 0.000 description 1
• 108090000915 Aminopeptidases Proteins 0.000 description 1
• 241000256844 Apis mellifera Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• UKGGPJNBONZZCM-WDSKDSINSA-N Asp-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O UKGGPJNBONZZCM-WDSKDSINSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101500025132 Bos taurus Ubiquitin Proteins 0.000 description 1
• 101500027500 Bos taurus Ubiquitin Proteins 0.000 description 1
• 101500027539 Bos taurus Ubiquitin Proteins 0.000 description 1
• 101500028979 Bos taurus Ubiquitin Proteins 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 241000225069 Calyptocephallela gayi Species 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 108050000299 Chemokine receptor Proteins 0.000 description 1
• 102000009410 Chemokine receptor Human genes 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 108010038061 Chymotrypsinogen Proteins 0.000 description 1
• GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 102000001189 Cyclic Peptides Human genes 0.000 description 1
• 108010069514 Cyclic Peptides Proteins 0.000 description 1
• 241000252206 Cypriniformes Species 0.000 description 1
• 102100025287 Cytochrome b Human genes 0.000 description 1
• 108010052832 Cytochromes Proteins 0.000 description 1
• 102000018832 Cytochromes Human genes 0.000 description 1
• 108010075028 Cytochromes b Proteins 0.000 description 1
• 108010003212 D-Ala(2),MePhe(4),Met(0)-ol-enkephalin Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• FHZPGIUBXYVUOY-VWGYHWLBSA-N Dermorphin Chemical class C([C@H](N)C(=O)N[C@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)C1=CC=C(O)C=C1 FHZPGIUBXYVUOY-VWGYHWLBSA-N 0.000 description 1
• 102400000242 Dynorphin A(1-17) Human genes 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 206010073306 Exposure to radiation Diseases 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 108010044495 Fetal Hemoglobin Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108010070675 Glutathione transferase Proteins 0.000 description 1
• 102000005720 Glutathione transferase Human genes 0.000 description 1
• 108010068370 Glutens Proteins 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 102000012428 Hematopoietic Cell Growth Factors Human genes 0.000 description 1
• 108010022580 Hematopoietic Cell Growth Factors Proteins 0.000 description 1
• 108091005886 Hemoglobin subunit gamma Proteins 0.000 description 1
• 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
• 101001035503 Homo sapiens Hemoglobin subunit delta Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 102000049772 Interleukin-16 Human genes 0.000 description 1
• 101800003050 Interleukin-16 Proteins 0.000 description 1
• 102100039064 Interleukin-3 Human genes 0.000 description 1
• 208000032177 Intestinal Polyps Diseases 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• 108010054278 Lac Repressors Proteins 0.000 description 1
• 102000004407 Lactalbumin Human genes 0.000 description 1
• 108090000942 Lactalbumin Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 241001440178 Massala Species 0.000 description 1
• IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
• GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
• HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
• 230000004988 N-glycosylation Effects 0.000 description 1
• SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 1
• UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
• APSUXPSYBJVPPS-YAUKWVCOSA-N Norbinaltorphimine Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C=3C[C@]4(O)[C@]67CCN(CC8CC8)[C@@H]4CC=4C7=C(C(=CC=4)O)O[C@H]6C=3NC=25)O)CC1)O)CC1CC1 APSUXPSYBJVPPS-YAUKWVCOSA-N 0.000 description 1
• 230000004989 O-glycosylation Effects 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 239000008896 Opium Substances 0.000 description 1
• 102000016978 Orphan receptors Human genes 0.000 description 1
• 108070000031 Orphan receptors Proteins 0.000 description 1
• 108010058846 Ovalbumin Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 208000006994 Precancerous Conditions Diseases 0.000 description 1
• 208000007541 Preleukemia Diseases 0.000 description 1
• 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
• 239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 206010061926 Purulence Diseases 0.000 description 1
• 102400000235 Rimorphin Human genes 0.000 description 1
• 101800001440 Rimorphin Proteins 0.000 description 1
• 241000220317 Rosa Species 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 101001083338 Sus scrofa Hemoglobin subunit alpha Proteins 0.000 description 1
• 101000990253 Sus scrofa Hemoglobin subunit beta Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 102100036407 Thioredoxin Human genes 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 241000209140 Triticum Species 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• 102000005937 Tropomyosin Human genes 0.000 description 1
• 108010030743 Tropomyosin Proteins 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• HPYDSVWYXXKHRD-VIFPVBQESA-N Tyr-Gly Chemical group [O-]C(=O)CNC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 HPYDSVWYXXKHRD-VIFPVBQESA-N 0.000 description 1
• VNYDHJARLHNEGA-RYUDHWBXSA-N Tyr-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 VNYDHJARLHNEGA-RYUDHWBXSA-N 0.000 description 1
• PAJVBIPSWDYNHN-UHFFFAOYSA-N Tyr-Pro-Trp-Thr-Gln-Arg-Phe Natural products C=1C=CC=CC=1CC(C(O)=O)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCC(N)=O)NC(=O)C(C(O)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCCN1C(=O)C(N)CC1=CC=C(O)C=C1 PAJVBIPSWDYNHN-UHFFFAOYSA-N 0.000 description 1
• 102000018390 Ubiquitin-Specific Proteases Human genes 0.000 description 1
• 108010066496 Ubiquitin-Specific Proteases Proteins 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 229960004150 aciclovir Drugs 0.000 description 1
• MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 150000001295 alanines Chemical class 0.000 description 1
• 229960001391 alfentanil Drugs 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 238000011316 allogeneic transplantation Methods 0.000 description 1
• 229960001349 alphaprodine Drugs 0.000 description 1
• UVAZQQHAVMNMHE-XJKSGUPXSA-N alphaprodine Chemical compound C=1C=CC=CC=1[C@@]1(OC(=O)CC)CCN(C)C[C@@H]1C UVAZQQHAVMNMHE-XJKSGUPXSA-N 0.000 description 1
• 239000001166 ammonium sulphate Substances 0.000 description 1
• 239000002269 analeptic agent Substances 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 238000002617 apheresis Methods 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 108010093581 aspartyl-proline Proteins 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 239000003613 bile acid Substances 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 229960001113 butorphanol Drugs 0.000 description 1
• IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 230000006652 catabolic pathway Effects 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 108010042445 cell-binding peptide P-15 Proteins 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 210000002791 cfu-m Anatomy 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 230000027288 circadian rhythm Effects 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 230000002281 colonystimulating effect Effects 0.000 description 1
• 238000009096 combination chemotherapy Methods 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 239000000039 congener Substances 0.000 description 1
• 208000035623 congenital anemia Diseases 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000011443 conventional therapy Methods 0.000 description 1
• NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
• 239000000287 crude extract Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 238000011033 desalting Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 229960004193 dextropropoxyphene Drugs 0.000 description 1
• XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 229960000920 dihydrocodeine Drugs 0.000 description 1
• RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000004821 effect on bone Effects 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 239000012149 elution buffer Substances 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 210000001339 epidermal cell Anatomy 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 238000011010 flushing procedure Methods 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000002695 general anesthesia Methods 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 235000021312 gluten Nutrition 0.000 description 1
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
• 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
• 108010036302 hemoglobin AS Proteins 0.000 description 1
• 108010022155 hemoglobin Portland Proteins 0.000 description 1
• 108010047910 hemorphin 7 Proteins 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 230000003284 homeostatic effect Effects 0.000 description 1
• 102000055276 human IL3 Human genes 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 230000000917 hyperalgesic effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 210000003000 inclusion body Anatomy 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000016507 interphase Effects 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 238000001155 isoelectric focusing Methods 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 238000004898 kneading Methods 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 231100000636 lethal dose Toxicity 0.000 description 1
• 229960000263 levallorphan Drugs 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 108010017286 macrophage inflammatory protein 1alpha receptor Proteins 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 108010019084 mastoparan Proteins 0.000 description 1
• MASXKPLGZRMBJF-MVSGICTGSA-N mastoparan Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O MASXKPLGZRMBJF-MVSGICTGSA-N 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 210000003593 megakaryocyte Anatomy 0.000 description 1
• MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 description 1
• 229960000365 meptazinol Drugs 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 229960001797 methadone Drugs 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 108010083475 myelopeptides Proteins 0.000 description 1
• 229960000805 nalbuphine Drugs 0.000 description 1
• NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
• 229960000938 nalorphine Drugs 0.000 description 1
• 239000002353 niosome Substances 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 231100000957 no side effect Toxicity 0.000 description 1
• 108010020615 nociceptin receptor Proteins 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 239000003402 opiate agonist Substances 0.000 description 1
• 230000000945 opiatelike Effects 0.000 description 1
• 229960001027 opium Drugs 0.000 description 1
• 229940092253 ovalbumin Drugs 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
• 229960005301 pentazocine Drugs 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 150000002994 phenylalanines Chemical class 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 230000008288 physiological mechanism Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920001993 poloxamer 188 Polymers 0.000 description 1
• 229920001987 poloxamine Polymers 0.000 description 1
• 108010054442 polyalanine Proteins 0.000 description 1
• 108010094020 polyglycine Proteins 0.000 description 1
• 229920000232 polyglycine polymer Polymers 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 229950008885 polyglycolic acid Drugs 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 235000015277 pork Nutrition 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 108010034422 pre-prodynorphin Proteins 0.000 description 1
• 230000001855 preneoplastic effect Effects 0.000 description 1
• 108010074732 preproenkephalin Proteins 0.000 description 1
• 230000002400 pro-nociceptive effect Effects 0.000 description 1
• 235000013930 proline Nutrition 0.000 description 1
• 239000011253 protective coating Substances 0.000 description 1
• 235000004252 protein component Nutrition 0.000 description 1
• 230000007065 protein hydrolysis Effects 0.000 description 1
• 238000000734 protein sequencing Methods 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 230000001950 radioprotection Effects 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 238000012807 shake-flask culturing Methods 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 238000010911 splenectomy Methods 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 230000023895 stem cell maintenance Effects 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 238000007801 sublethal irradiation Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 108060008226 thioredoxin Proteins 0.000 description 1
• 229940094937 thioredoxin Drugs 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 231100000167 toxic agent Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 108010020532 tyrosyl-proline Proteins 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 235000014393 valine Nutrition 0.000 description 1
• 150000003680 valines Chemical class 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 235000021249 α-casein Nutrition 0.000 description 1
• 235000021247 β-casein Nutrition 0.000 description 1